Stay updated with breaking news from Mark Rus. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Delix Therapeutics (the "Company"), a preclinical neuroscience company developing novel disease-modifying therapeutics for serious psychiatric...
Delix Therapeutics Retains KCSA Strategic Communications KCSA to provide integrated public and investor relations counsel News provided by Share this article Share this article BOSTON, May 19, 2021 /PRNewswire/ -- Delix Therapeutics (the "Company"), a preclinical biotech company developing novel disease-modifying therapeutics for serious psychiatric and neurological conditions, today announced that it has retained KCSA Strategic Communications, a leading integrated communications firm, as its agency of record (AOR). KCSA will implement a comprehensive strategic communications program that aim...
Share: BOSTON, April 28, 2021 /PRNewswire/ -- Delix Therapeutics, a preclinical biotech company developing novel disease-modifying therapeutics for serious psychiatric and neurological conditions, lauded a study published today in the highly-regarded scientific journal Cell by Delix Co-founder and Chief Scientific Officer, Professor David E. Olson, PhD. The paper, co-authored by Olson and collaborator Lin Tian, PhD, both of whom are professors at the University of California, Davis, reveals DLX-1—a new compound inspired by the chemical structures of common psychedelic substances that dem...
Share this article Share this article BOSTON, April 28, 2021 /PRNewswire/ -- Delix Therapeutics, a preclinical biotech company developing novel disease-modifying therapeutics for serious psychiatric and neurological conditions, lauded a study published today in the highly-regarded scientific journal Cell by Delix Co-founder and Chief Scientific Officer, Professor David E. Olson, PhD. The paper, co-authored by Olson and collaborator Lin Tian, PhD, both of whom are professors at the University of California, Davis, reveals DLX-1—a new compound inspired by the chemical structures of common ...